Ford v. New York State Racing & Wagering BoardFord v. New York State Racing & Wagering Board
McCarthy, J. Appeal from a judgment of the Supreme Court (Powers, J.), entered August 15, 2011 in Schenectady County, which granted petitioners’ application, in a proceeding pursuant to
In 2009, respondent1 adopted regulations that prohibited the use of certain performance enhancing substances in racehorses, and permitted respondent to drug test all racehorses under the care or control of a trainer licensed by respondent that are anticipated to compete in a race at a New York racetrack within six months (see
Supreme Court erred in finding that respondent lacked the statutory authority to adopt regulations permitting out-of-competition drug testing of harness racehorses.
Contrary to petitioners’ contentions, nothing in the
Having determined that respondent had the authority to adopt the regulation, we now look to its substance. This Court should uphold a regulation if it has a rational basis and is not unreasonable, arbitrary or capricious (see Kuppersmith v Dowling, 93 NY2d 90, 96 [1999]; Matter of Sullivan Fin. Group, Inc. v Wrynn, 94 AD3d 90, 94 [2012]; Matter of Quagliata v Starbucks Coffee, 82 AD3d 1321, 1322 [2011], lv denied 17 NY3d 703 [2011]). Here, the objective of the out-of-competition drug testing regulation, as stated by respondent when it was proposed, is “[t]o enable [respondent] to assure the public‘s confidence and preserve the integrity of racing at pari-mutuel betting tracks by regulating the use of drugs and medications in race horses so that their natural racing ability is not compromised or enhanced by such use.” Prior to the adoption of the regulation at issue, respondent was permitted to conduct pre and postrace on-track drug testing, but there was no provision permitting respondent “to detect and deter the administration of prohibited performance-enhancing drugs and substances in race horses that are not stabled on the grounds of a racetrack.” According to George Maylin, the director of respondent‘s drug testing and research program, the existing drug testing scheme was insufficient to detect when an unscrupulous owner or trainer had “doped” a horse in order to enhance its performance because new doping agents exist that can be administered to a horse off-track many weeks in advance of a race and then clear out of the horse‘s system so that they are not detectable in a blood sample taken on the day of the race. Maylin averred that the only reliable way to detect whether a horse had been given these new performance-enhancing agents is to test the horse off-track, well in advance of a race.
The 180-day testing window was not wholly arbitrary or capricious. As Maylin explained, the prohibited doping agents can remain “efficacious for many weeks or longer” and “affect performance long after the drug can be detected.” Accordingly, respondent identified a 180-day window prior to competition in which horses may be tested (see
Respondent contends that Supreme Court further erred by declaring arbitrary the regulation‘s requirement that a licensed owner or trainer, upon respondent‘s request, bring to a New York track any racehorse that is stabled out-of-state within 100 miles of the track (see
Supreme Court erred in finding that the regulation impermissibly infringed on the legal rights of individuals not licensed by
The regulation only requires any “trainer, owner and/or their designees and any licensed racing corporation” to cooperate with respondent regarding testing (
Supreme Court erred in striking down the regulation‘s penalty against a trainer for a positive drug test. Although the regulation provides for a minimum penalty of a 10-year suspension, the trainer can receive a lower penalty by demonstrating “extraordinary mitigating circumstances” (
Supreme Court found that the list of prohibited substances was both vague and inconsistent with other regulations permitting the use of certain substances. The regulation at issue defines “[p]rohibited substances” as “(1) blood doping agents including” specifically listed substances, “or any substance that abnormally enhances the oxygenation of body tissues; (2) gene doping agents or the nontherapeutic use of genes, genetic elements, and/or cells that have the capacity to enhance athletic performance or produce analgesia; (3) protein and peptide-based drugs, including toxins and venoms” (
Subparagraph (e) (3) of
Rose, J.P., Spain and Egan Jr., JJ., concur. Ordered that the judgment is modified, on the law, without costs, by reversing so much thereof as annulled and enjoined respondent from enforcing all portions of